Exosomes may be used to identify somatic mutations of tumors from liquid biopsies [8, 69], with EGFR and its signaling network proteins frequently detected in exosomes from NSCLC patients, making them potential biomarkers for cancer research and clinical use [75, 76, 78]. This evidence concerns the gene EGFR and cancer.